Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
432 studies found for:    Expanded Access Studies
Show Display Options
Rank Status Study
21 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
22 No longer available Treatment With Crizotinib Single Patient Expanded Access IND 134375
Condition: Inflammatory Myofibroblastic Tumour
Intervention: Drug: Crizotinib
23 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
24 Available Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Conditions: Cholestasis;   Liver Diseases
Intervention: Drug: Omegaven
25 Available Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Conditions: Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Intervention: Drug: ASP2215
26 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
27 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
28 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib
29 Temporarily not available Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan
Condition: PSR Ovarian Cancer With a BRCA Mutation
Intervention: Drug: olaparib
30 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
31 Available Expanded Access to RXDX-105 for Cancers With RET Alterations
Condition: Cancers With RET Alterations
Intervention: Drug: RXDX-105
32 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
33 Approved for marketing Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Niraparib
34 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
35 Available Dupilumab Compassionate Use Study
Condition: Asthma
Intervention: Drug: Dupilumab
36 Temporarily not available A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Drug: 131-I-meta-iodobenzylguanidine
37 No longer available Study of Cannabidiol for Drug-Resistant Epilepsies
Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
38 Temporarily not available Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
Conditions: CMV Viremia;   CMV Disease
Intervention: Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
39 No longer available Single Patient IND, MLN8237
Condition: Prostate Cancer
Intervention: Drug: MLN8237
40 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.